MX2021005168A - Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. - Google Patents

Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.

Info

Publication number
MX2021005168A
MX2021005168A MX2021005168A MX2021005168A MX2021005168A MX 2021005168 A MX2021005168 A MX 2021005168A MX 2021005168 A MX2021005168 A MX 2021005168A MX 2021005168 A MX2021005168 A MX 2021005168A MX 2021005168 A MX2021005168 A MX 2021005168A
Authority
MX
Mexico
Prior art keywords
breast cancer
compositions
methods
antisense
treating breast
Prior art date
Application number
MX2021005168A
Other languages
English (en)
Inventor
Douglas Craig Hooper
David Andrews
Aurore Lebrun
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021005168A publication Critical patent/MX2021005168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a composiciones y métodos para tratar cáncer de mama usando ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina (IGF-1R). El AS se puede administrar a los pacientes de forma sistémica o se puede usar para producir una vacuna de células cancerosas autólogas. En modalidades, los AS se proveen en una cámara de biodifusión irradiada implantable que comprende células tumorales y una cantidad eficaz de AS. Las cámaras se irradian e implantan en el abdomen de los sujetos y estimulan una respuesta inmunológica que ataca a los tumores distalmente. Las composiciones y métodos descritos en este documento pueden usarse para tratar muchos tipos diferentes de cáncer de mama, incluyendo el cáncer de mama metastásico.
MX2021005168A 2018-11-02 2019-10-31 Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. MX2021005168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755094P 2018-11-02 2018-11-02
PCT/US2019/059021 WO2020092684A1 (en) 2018-11-02 2019-10-31 Methods and compositions for treating breast cancer using antisense

Publications (1)

Publication Number Publication Date
MX2021005168A true MX2021005168A (es) 2021-08-24

Family

ID=70464228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005168A MX2021005168A (es) 2018-11-02 2019-10-31 Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.

Country Status (7)

Country Link
US (1) US20220000916A1 (es)
EP (1) EP3873497A4 (es)
JP (1) JP2022512894A (es)
AU (1) AU2019372132A1 (es)
CA (1) CA3118427A1 (es)
MX (1) MX2021005168A (es)
WO (1) WO2020092684A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206942B2 (en) * 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
SG11201908054XA (en) * 2017-03-09 2019-09-27 Univ Jefferson Methods and compositions for treating cancers using antisense
AU2018254485A1 (en) * 2017-04-19 2019-10-31 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for IGF-1R inhibition

Also Published As

Publication number Publication date
CA3118427A1 (en) 2020-05-07
US20220000916A1 (en) 2022-01-06
EP3873497A1 (en) 2021-09-08
EP3873497A4 (en) 2022-08-03
WO2020092684A1 (en) 2020-05-07
AU2019372132A1 (en) 2021-06-03
JP2022512894A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
MX2019010725A (es) Metodos y composiciones para tratar canceres usando antisentido.
CN108030919B (zh) 人血清白蛋白修饰黑磷量子点的制备及作为增敏剂的应用
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
WO2019055880A3 (en) Method of administration and treatment
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
RU2012127685A (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
JP2015516496A5 (es)
EP4023233A3 (en) Optimized oncolytic viruses and uses thereof
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
Whelan et al. Interim toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation (APBI) using 3D conformal external beam radiation therapy (3D CRT)
EP1723963A3 (en) Hapten-conjugated tumour cells
MX2021005168A (es) Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
Faries Intralesional immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology
AR027362A1 (es) Celula tumoral haptenizada de baja dosis e inmunoterapia de extracto celular tumoral
Tong et al. Inhibiting human breast cancer cells (mcf-7) with alternating micro-current at intermediate frequency (acif) in vitro and in vivo
Kim et al. Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma
Safonova et al. Correction of damaging effects of cisplatin-containing polychemotherapy on the intestinal epithelium with Tussilago farfara L. Polysaccharides.
CN106456687A (zh) 包含辣木叶提取物的放射线联合处理用组合物及利用其的治疗方法
WO2021127556A8 (en) Methods for treating cancer comprising low dose radiation
MX2023004899A (es) Direccionamiento de src-3 en celulas inmunitarias como un inmunomodulador terapeutico para el tratamiento de cancer.
GB2419530A (en) Human prostate cell lines in cancer treatment
Van Limbergen et al. The usefull boost range (UBR) concept judges the ballistic selectivity of electron beams (EB) versus brachytherapy (BT) in the boost techniques of breast conserving therapy
CN101898012A (zh) 一种增强高强度聚焦超声诱导的抗肿瘤免疫应答的方法